Wegovy Pill: Everything We Know

For four years, getting semaglutide for weight loss meant a weekly injection. That changed on December 22, 2025, when FDA approved Wegovy tablets, the first oral GLP-1 approved in the United States for weight management [2]. The pill reached US pharmacies on Monday, January 5, 2026, with the starting dose first and the higher strengths later that week [11].

Here is what the label actually says, what the trial data showed, and what it costs.

What is the Wegovy pill?

It is semaglutide, the same active ingredient as the Wegovy injection, in a once-daily tablet that reaches a 25 mg maintenance dose [1].

That number sounds enormous next to the 2.4 mg injection, and there is a reason. Semaglutide is a peptide, and peptides get broken down in the stomach. The tablet uses an absorption enhancer to get a fraction of the dose into the bloodstream, so the milligram figure on the bottle is not comparable to the milligram figure on the pen.

The pill is approved for two things, both in combination with a reduced-calorie diet and increased physical activity [1]:

• Reducing the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight
• Reducing excess body weight and maintaining weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition

Notably, the pill is approved for adults only. The label says it is not known whether Wegovy tablets are safe and effective in people under 18 [1]. The injection, by contrast, covers adolescents 12 and older.

What doses does the Wegovy pill come in?

Four strengths, each a step on a 30-day ladder [1]:

Days	Dose
1 through 30	1.5 mg once daily
31 through 60	4 mg once daily
61 through 90	9 mg once daily
91 and onward	25 mg once daily (maintenance)

The 1.5, 4 and 9 mg tablets are round; the 25 mg tablet is oval. All are white to light yellow and debossed with the strength on one side and “novo” on the other [1]. They come in bottles of 30.

How do you take the Wegovy pill?

This is the part people underestimate. The label is specific [1]:

• Take one tablet once daily, in the morning, on an empty stomach
• Use no more than 4 ounces of water. No coffee, no juice, no other liquid
• Swallow the tablet whole. Do not split, crush, chew or dissolve it
• Wait at least 30 minutes before eating, drinking anything else or taking any other oral medicine
• Do not take more than one tablet a day

If you miss a dose, the label says to skip it and take the next dose the following day [1].

That 30-minute window is not a suggestion. The absorption enhancer only works properly in an empty stomach, and food or other liquids reduce how much semaglutide gets absorbed. If your mornings are chaotic, it is worth being honest about that with your prescriber before you start.

How much weight did people lose on the Wegovy pill?

The approval rested on the OASIS trial program plus the SELECT cardiovascular trial [2].

In OASIS 4, a 64-week study in 307 participants with obesity or overweight with a related condition [2]:

• Average weight loss was about 16.6% among people who stayed on treatment, compared with roughly 3% on placebo
• Counting every randomized participant regardless of adherence, it was about 14% versus 2%
• About 76% of participants reached at least 5% weight loss, compared with 31% on placebo
• Roughly one in three lost 20% of their body weight or more

For a 220-pound person, 16.6% is about 36 pounds. But averages hide a wide spread, and trial participants get structured diet and activity support that most people do not have at home.

How does the pill compare with the Wegovy injection?

They were studied in different trials, so there is no clean head-to-head number. Broadly, the 2.4 mg injection has produced average weight loss in the high teens in its trials, and the newer 7.2 mg Wegovy HD dose reached about 20.7% at 72 weeks in STEP UP among people who stayed on treatment. The 25 mg pill landed at about 16.6% in OASIS 4 over 64 weeks.

The practical differences matter more for most people:

	Wegovy pill	Wegovy injection
How often	Once daily	Once weekly
Routine	Empty stomach, 4 oz water, 30-minute wait	Any time of day, with or without food
Storage	Room temperature, in the original bottle	Refrigerated; limited time at room temperature
Needles	None	Hidden needle in a single-dose pen
Ages	Adults only	Adults and children 12 and older
Highest dose	25 mg	7.2 mg (Wegovy HD)
MASH indication	No	Yes, for F2-F3 fibrosis

The label also gives explicit switching instructions. Someone taking the 2.4 mg injection for cardiovascular risk or weight reduction may switch to 25 mg tablets, starting the tablets one week after the last injection. Someone on 25 mg tablets may switch to the injection starting the day after the last tablet, and if they did not tolerate 25 mg tablets, the label suggests considering the 1.7 mg injection instead of 2.4 mg [1].

What does the Wegovy pill cost?

Novo Nordisk publishes self-pay prices by dose [3][4]:

Dose	Self-pay price per month
1.5 mg	$149
4 mg	$199
9 mg	$299
25 mg	$299

The 4 mg dose was offered at $149 through August 31, 2026, after which the published price moved to $199 [4]. One month is defined as one bottle of 30 tablets.

If you have commercial insurance that covers Wegovy, the savings card can bring the cost to as little as $25 a month, subject to a maximum saving of $100 a month. Government beneficiaries are excluded from that card [3].

There are two other routes worth knowing about:

Subscription pricing. On March 31, 2026 Novo Nordisk launched a multi-month subscription for self-pay patients through select telehealth partners, initially Ro, WeightWatchers and LifeMD, with Hims & Hers and Sesame named as coming [5]. Longer commitments get lower monthly prices. Novo Nordisk’s own announcement gives the tiers as $329, $299 and $249 a month for the Wegovy pen on three-, six- and twelve-month plans, and $289, $269 and $249 for the 9 mg or 25 mg pill. These are self-pay subscription tiers, not insurance prices, and telehealth platforms may add their own consultation or membership fees. Novo Nordisk said the arrangement saves up to $600 a year on the pill and up to $1,200 a year on the injection [5][6]. Wegovy HD 7.2 mg was to be added later.

Medicare. Eligible Medicare Part D enrollees can access all dose strengths of the Wegovy pen and pill for $50 a month starting July 1, 2026 under the CMS Medicare GLP-1 Bridge demonstration, which runs through December 31, 2027 [7]. A prior authorization request from the prescriber is required, and eligibility criteria are set by CMS.

Is the Wegovy pill the same as the Ozempic pill?

No, and this trips people up constantly because both are oral semaglutide.

The Ozempic pill, which launched May 4, 2026, comes in 1.5, 4 and 9 mg and is approved for type 2 diabetes and for reducing cardiovascular events in adults with type 2 diabetes at high risk [9]. It is the reformulated product that used to be sold as Rybelsus.

The Wegovy pill has a fourth strength, 25 mg, and is approved for weight management and cardiovascular risk in people with obesity or overweight [1].

The two share the same 1.5, 4 and 9 mg steps during escalation, but they diverge at the top and they carry different labels. The prescribing information says not to use a semaglutide product alongside another semaglutide product or any other GLP-1 receptor agonist [1].

What about Foundayo, the other new weight-loss pill?

Foundayo (orforglipron), approved April 1, 2026, is Eli Lilly’s once-daily oral GLP-1 for weight management [8]. It is a different kind of molecule: a small-molecule non-peptide, which means it does not need the absorption enhancer that forces the empty-stomach routine. Lilly’s label allows taking it at any time of day, with or without food or water restrictions [8].

In ATTAIN-1, participants on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4%, over 72 weeks, against 2.2 pounds (0.9%) on placebo [8]. Published trial reports describe that arm as 36 mg, which is the investigational capsule equivalent to the marketed 17.2 mg Foundayo tablet.

There has been no head-to-head trial between the Wegovy pill and Foundayo. Comparisons published so far are indirect, and indirect comparisons across different trials should be read with caution.

What are the side effects?

The most common reactions reported with the Wegovy pill were nausea, vomiting and diarrhea [2]. The broader Wegovy label lists constipation, stomach pain, headache, fatigue, upset stomach, dizziness, bloating, belching, gas, heartburn and nasal or throat symptoms among reactions occurring in 5% or more of patients [1].

The label carries a boxed warning: in rodents, semaglutide caused thyroid C-cell tumors at clinically relevant exposures, and it is unknown whether it does so in humans. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [1].

Other warnings in the label include pancreatitis, gallbladder disease, low blood sugar (especially alongside insulin or sulfonylureas), dehydration leading to kidney problems, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and the risk of food or liquid entering the lungs during anesthesia or deep sedation [1].

One label change worth flagging: the Suicidal Behavior and Ideation warning is gone. On January 13, 2026 FDA issued a Drug Safety Communication reporting that a review of 91 placebo-controlled trials covering 107,910 participants found no increased risk of suicidal behavior or ideation with GLP-1 medicines, and asked the makers of Saxenda, Wegovy and Zepbound to strike the warning [10]. The Recent Major Changes section of the current Wegovy prescribing information records the removal as 01/2026 [1].

For breastfeeding, the label specifically says breastfeeding is not recommended during treatment with Wegovy tablets [1].

Who should not take it?

Beyond the thyroid contraindications, the label says not to use Wegovy if you have had a serious allergic reaction to semaglutide or any ingredient in the product. The manufacturer’s consumer materials also say Wegovy may harm an unborn baby and that people should stop it two months before planning to become pregnant [1].

Any decision about starting, switching or stopping belongs with a healthcare provider who knows your history.

Sources

1. WEGOVY (semaglutide) injection and tablets - US Prescribing Information, Novo Nordisk
2. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults - PR Newswire, December 22, 2025
3. Wegovy price guide - NovoCare
4. Wegovy Cost & Coverage Information - Novo Nordisk
5. Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy - PR Newswire, March 31, 2026
6. Novo Nordisk rolls out discounted subscription plan for Wegovy - Fierce Healthcare
7. CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
8. FDA approves Lilly’s Foundayo (orforglipron) - Eli Lilly and Company, April 1, 2026
9. RYBELSUS and OZEMPIC (semaglutide) tablets - US Prescribing Information
10. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications - US Food and Drug Administration, January 13, 2026
11. Wegovy obesity pill now available at pharmacies - NPR, January 5, 2026

This article is general information, not medical advice. Talk to a healthcare provider about whether this medicine is appropriate for you.